bg4 Team shape

leadership team

Dr. Michael Presti Team Shape

Dr. Michael Presti, M.D. PH.D.

FOUNDER - CEO
Raymundo Sison Team Shape

Raymundo Sison, M.S.

CPO
JOE SUAREZ Team Shape

JOE SUAREZ, M.B.A.

CFO
advisory-bg

advisory board

team Team
  • Co-founded two highly successful life science companies: RTI Surgical, Inc. and AxoGen, Inc., both now publicly traded (NASDAQ: RTIX, AXGN)
  • Former CEO of Florida Institute for Commercialization of Public Research
  • Visionary and innovator in medical technology, regenerative medicine
  • Successfully launched, managed, or advised numerous biotech startup companies
  • Accomplished pharmaceutical executive with >25 years of demonstrated success developing brand name and generic drug products, Dr. Bittorf has taken more than 30 products to market.
  • Leadership positions with Curis Inc., Flatley Discovery Lab, Trek Therapeutics, Compaction Simulation Forum, Living Proof Inc., and Vertex Pharmaceuticals.
  • Deep expertise with GMP, risk management, business development, regulatory process, and formulation and manufacturing techniques from feasibility through commercialization stages.
  • Excels at driving innovation resulting in cost savings and improved product control, engaging stakeholders to secure funding for technology investments, and leading regulatory submissions of Quality by Design initiatives.
  • World-renowned addiction expert with 45+ years of experience studying effects of opioids and other drugs
  • Authored over 1000 articles, chapters and abstracts in scientific journals
  • Former Consultant to White House Office of Drug Policy
  • Emeritus Eminent Scholar, Distinguished Professor and former Chair of Psychiatry at the University of Florida
  • Director of Research, Drug Enforcement Agency (DEA) Educational Foundation
  • Addiction expert and prominent advocate for treatment of drug addiction, criminal justice reform, and developing resources to help families in crisis
  • President and CEO of the Addiction Policy Forum
  • Appointee to Presidential Drug-Free Communities Commission
  • Contributed to national drug-related legislative policy, including the Second Chance Act, the Drug Impaired Driving Act, the Drug-Free Workplace Act, and the Drug Free Communities Act
  • Managing director and co-head of the M&A Buyside Advisory at Fifth Third Securities
  • Managing director at Praxis Partners LLC
  • Expert in corporate valuation, M&A, venture finance, entrepreneurship, corporate strategy, cross-border acquisitions
  • CPA with 30+ years of operational, strategic and transactional M&A advisory experience
  • Over two decades Product Development experience in Medical Device, HCT/Ps, Biologic, and Pharmaceutical industries
  • Directed R&D at AuxThera Inc., AxoGen Inc. (NASDAQ: AXGN), RTI Surgical, Inc. (NASDAQ: RTIX) and other biotechnology companies
  • Brings practical expertise especially for startup and small to mid-size companies
  • Jamie Grooms

    Jamie Grooms

    EXECUTIVE BOARD
  • Dr. KEVIN BITTORF

    Dr. KEVIN BITTORF, Ph.D. M.B.A.

    SCIENTIFIC ADVISORY BOARD
  • Dr. Mark Gold

    Dr. Mark Gold, M.D.

    SCIENTIFIC ADVISORY BOARD
  • Jessica Hulsey-Nickel

    Jessica Hulsey-Nickel

    SCIENTIFIC ADVISORY BOARD
  • dr. JIM PARRINO

    dr. JIM PARRINO, Ph.D. M.B.A.

    EXECUTIVE BOARD
  • MARLO TAN WALPOLE

    MARLO TAN WALPOLE

    EXECUTIVE BOARD
  • Jamie Grooms

    Jamie Grooms

    EXECUTIVE BOARD
    • Co-founded two highly successful life science companies: RTI Surgical, Inc. and AxoGen, Inc., both now publicly traded (NASDAQ: RTIX, AXGN)
    • Former CEO of Florida Institute for Commercialization of Public Research
    • Visionary and innovator in medical technology, regenerative medicine
    • Successfully launched, managed, or advised numerous biotech startup companies
  • Dr. KEVIN BITTORF

    Dr. KEVIN BITTORF, Ph.D. M.B.A.

    SCIENTIFIC ADVISORY BOARD
    • Accomplished pharmaceutical executive with >25 years of demonstrated success developing brand name and generic drug products, Dr. Bittorf has taken more than 30 products to market.
    • Leadership positions with Curis Inc., Flatley Discovery Lab, Trek Therapeutics, Compaction Simulation Forum, Living Proof Inc., and Vertex Pharmaceuticals.
    • Deep expertise with GMP, risk management, business development, regulatory process, and formulation and manufacturing techniques from feasibility through commercialization stages.
    • Excels at driving innovation resulting in cost savings and improved product control, engaging stakeholders to secure funding for technology investments, and leading regulatory submissions of Quality by Design initiatives.
  • Dr. Mark Gold

    Dr. Mark Gold, M.D.

    SCIENTIFIC ADVISORY BOARD
    • World-renowned addiction expert with 45+ years of experience studying effects of opioids and other drugs
    • Authored over 1000 articles, chapters and abstracts in scientific journals
    • Former Consultant to White House Office of Drug Policy
    • Emeritus Eminent Scholar, Distinguished Professor and former Chair of Psychiatry at the University of Florida
    • Director of Research, Drug Enforcement Agency (DEA) Educational Foundation
  • Jessica Hulsey-Nickel

    Jessica Hulsey-Nickel

    SCIENTIFIC ADVISORY BOARD
    • Addiction expert and prominent advocate for treatment of drug addiction, criminal justice reform, and developing resources to help families in crisis
    • President and CEO of the Addiction Policy Forum
    • Appointee to Presidential Drug-Free Communities Commission
    • Contributed to national drug-related legislative policy, including the Second Chance Act, the Drug Impaired Driving Act, the Drug-Free Workplace Act, and the Drug Free Communities Act
  • dr. JIM PARRINO

    dr. JIM PARRINO, Ph.D. M.B.A.

    EXECUTIVE BOARD
    • Managing director and co-head of the M&A Buyside Advisory at Fifth Third Securities
    • Managing director at Praxis Partners LLC
    • Expert in corporate valuation, M&A, venture finance, entrepreneurship, corporate strategy, cross-border acquisitions
    • CPA with 30+ years of operational, strategic and transactional M&A advisory experience
  • MARLO TAN WALPOLE

    MARLO TAN WALPOLE

    EXECUTIVE BOARD
    • Over two decades Product Development experience in Medical Device, HCT/Ps, Biologic, and Pharmaceutical industries
    • Directed R&D at AuxThera Inc., AxoGen Inc. (NASDAQ: AXGN), RTI Surgical, Inc. (NASDAQ: RTIX) and other biotechnology companies
    • Brings practical expertise especially for startup and small to mid-size companies
footer-shape